Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wright State Physicians Inc

Neither a doctor nor a teaching hospital

Research payments

$3,546,765

226 payments

Through program year 2025, Wright State Physicians Inc is reported as receiving $3,546,765 in research payments, across 226 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $330,175 67
2024 Research $291,782 54
2023 Research $162,682 29
2022 Research $221,532 32
2021 Research $223,613 14
2020 Research $182,492 12
2019 Research $2,134,489 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,568,072 10 payments
  2. Eli Lilly and Company $1,075,755 41 payments
  3. AbbVie, Inc. $327,992 89 payments
  4. Janssen Research & Development, LLC $297,389 41 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $188,541 25 payments
  6. Argenx US, Inc. $70,962 16 payments
  7. Sun Pharmaceutical Industries Inc. $13,500 2 payments
  8. Celgene Corporation $4,500 1 payment
  9. Ucb SA $54 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $1,564,922 3 payments
  2. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $236,405 5 payments
  3. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $215,786 4 payments
  4. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $174,600 3 payments
  5. A Phase 2a2b Multi Center Randomized Placebo and Active Comparator controlled Double Blind Dose ranging Study to Evaluate the Safety and Efficacy of Bermekimab JNJ77474462 for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa. $136,195 8 payments
  6. A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $123,043 5 payments
  7. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $108,885 12 payments
  8. Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $105,257 17 payments
  9. A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants $101,784 18 payments
  10. Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-To-Severe Plaque Psoriasis $80,135 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record